Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.
Olivia RuhenNathalie S M LakJanine StutterheimSara G DanielliMathieu ChicardYasmine IddirAlexandra Saint-CharlesVirginia Di PaoloLucia TombolanSusanne Andrea GatzEwa AladowiczPaula ProszekSabri JamalReda StankunaiteDeborah HughesPaul CarterElisa IzquierdoAjla WastiJulia C ChisholmSally L GeorgeErika PaceLouis CheslerIsabelle AertsGaëlle PierronSakina ZaidiOlivier DelattreDidier SurdezAnna KelseyMichael HubankPaolo BonviniGianni BisognoAngela Di GiannataleGudrun SchleiermacherBeat W SchäferGodelieve A M TytgatJanet ShipleyPublished in: JCO precision oncology (2022)
Comprehensive ctDNA analysis combining high sensitivity and throughput can identify key molecular drivers in RMS models and patients, suggesting potential as a minimally invasive biomarker. Preclinical assessment of treatments using mouse models and further patient testing through prospective clinical trials are now warranted.
Keyphrases
- circulating tumor
- cell free
- clinical trial
- circulating tumor cells
- minimally invasive
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- mouse model
- prognostic factors
- stem cells
- randomized controlled trial
- patient reported outcomes
- cell therapy
- open label
- mesenchymal stem cells
- study protocol